Neurotherapeutics · NeuroImmunomics™ at Time Zero
What if neurodegeneration were detectable and treatable, prior to the onset of clinical symptoms?
What if the human immune response carries the code for identifying and treating these diseases?
What if these discoveries unlock a breakthrough generation of precision neurotherapeutics?
Our vision
Reimagine the treatment of brain injury and neurodegenerative disease through a deeper understanding of human biology.
Calysas Therapeutics is developing a novel generation of targeted therapeutics for neurodegenerative disease, powered by NeuroImmunomics™ at Time Zero.
Precision approach
From human signal to precision.
Human data are decoded using the proprietary MOSAIC method, with clinical metadata overlay, and purpose-built, proprietary AI/ML — to rapidly identify novel drug targets, paired predictive biomarkers, and precision neurotherapeutics.
Human immune signal
Patient-derived antibody records of brain injury.
MOSAIC screen
Proprietary decoding of immune biology.
Clinical metadata
Overlay of real-world clinical context.
Proprietary AI/ML
Purpose-built models surface targets & biomarkers.
Output
- Novel drug targets ✦
- Paired predictive biomarkers ✦
- Precision neurotherapeutics ✦
Time Zero · Time Zero
Initial focus · TBI
70k+
Americans die from traumatic brain injury each year.
More than 70k Americans die from TBI each year, and millions more live with the debilitating impacts of the disease. Yet no disease modifying therapies exist, with care restricted to symptomatic interventions and support.
Expansion
Therapeutics for neurodegenerative conditions such as CTE, dementias, and parkinsonism.
